Zeria Pharmaceutical Co., Ltd. announced plans to cancel 1,000,000 shares of common stock (1.96% of the total outstanding shares) on February 25, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4559-20260205-02.pdf","jir_short_summary":"Zeria Pharmaceutical Co., Ltd. announced plans to cancel 1,000,000 shares of common stock (1.96% of the total outstanding shares) on February 25, 2026.","jir_summary":"### Overview of Capital Policy\nAt the Board of Directors meeting held on February 5, 2026, Zeria Pharmaceutical Co., Ltd. resolved to cancel treasury stock pursuant to Article 178 of the Companies Act. The shares to be canceled consist of 1,000,000 shares of common stock, representing approximately 1.96% of the total outstanding shares before the cancellation. The scheduled cancellation date is February 25, 2026, after which the total outstanding shares will be 50,119,190.\n\n### Impact on Shareholders\nThis treasury stock cancellation will reduce the total number of outstanding shares, which is expected to enhance the value per share. The number of canceled shares represents about 1.96% of the total outstanding shares, aiming to eliminate dilution and improve capital efficiency. There is no information provided regarding the use of funds or specific financial impacts.","jir_financial_highlights":"Total number of shares to be canceled: 1,000,000 shares (Percentage of total outstanding shares: 1.96%)\nScheduled cancellation date: 2026-02-25 (Unknown)\nTotal outstanding shares after cancellation: 50,119,190 shares (Unknown)","jir_category":"","jir_hashtags":"#ZeriaPharmaceutical, #TreasuryStockCancellation, #JapaneseStocks","jir_key_figures":"Total number of shares to be canceled: 1,000,000 shares (1.96% of total outstanding shares)\nScheduled cancellation date: 2026-02-25\nTotal outstanding shares after cancellation: 50,119,190 shares","jir_meta_title":"Zeria Pharmaceutical to Cancel 1,000,000 Common Shares (1.96%) on February 25, 2026","jir_meta_description":"Zeria Pharmaceutical Co., Ltd. resolved at the Board meeting on February 5, 2026, to cancel 1,000,000 treasury shares, equivalent to 1.96% of total outstanding shares, with cancellation scheduled for February 25.","jir_og_title":"Zeria Pharmaceutical Announces Cancellation of 1,000,000 Treasury Shares","jir_og_description":"Zeria Pharmaceutical Co., Ltd. announced plans to cancel 1,000,000 common shares on February 25, 2026. The total outstanding shares will become 50,119,190 after cancellation.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-24843","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n